DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Balaji Prasad - 2 Prasad - 1 Nexplanon - 1 — CNBC's Michael Bloom - 1 Amneal - 1 Raghav Mahobe - 1 Khushi - 1 Sriparna Roy - 1
Top related locs:
Wednesday's U.S Bengaluru
Top related orgs:
Barclays - 2 Merck - 1 Health - 1 U.S . Food - 1 Drug Administration - 1 Amneal Pharmaceuticals - 1 FDA - 1 Thomson - 1

Search resuls for: "Balaji Prasad"


2 mentions found


☆ Barclays says this women's health pharma company could rally 48%
  + stars: | 2023-09-21 | by ( Hakyung Kim | ) www.cnbc.com   time to read: +2 min
Organon is an undervalued global play and leader in women's specialty health, according to Barclays. The company, with a portfolio of about 60 treatments and products focused on women's health, was spun off from Merck in 2021 . Barclays analyst Balaji Prasad initiated coverage on Organon with an overweight rating. The company could also generate more than $1 billion in annual free cash flow during that span, he added. Organon's prescription birth control Nexplanon is the key driver to its women's health portfolio as the Nexplanon "pipeline continues to progress toward commercialization," he added.
Persons: Balaji Prasad, Prasad, Nexplanon, — CNBC's Michael Bloom Organizations: Barclays, Merck, Health Locations: Wednesday's
☆ US FDA declines to approve Amneal's Parkinson's drug over safety concerns
  + stars: | 2023-07-03 | by ( ) www.reuters.com   time to read: +2 min
July 3 (Reuters) - The U.S. Food and Drug Administration (FDA) has declined to approve Amneal Pharmaceuticals' (AMRX.N) drug designed to help control symptoms in Parkinson's disease patients for a longer duration, citing inadequate safety data. The complete response letter comes as a surprise, said Barclays analyst Balaji Prasad. The decision does not impact 2023 forecast as it did not include the revenue from the drug, the company said. Amneal has another Parkinson's drug, Rytary, on the market but has been struggling to gain a foothold in the treatment space. Only 4% of patients use the drug since its approval in 2015, as per company estimates.
Persons: Balaji Prasad, Amneal, Raghav Mahobe, Khushi, Sriparna Roy, Pooja Desai, Shweta Agarwal, Sriraj Organizations: U.S . Food, Drug Administration, Amneal Pharmaceuticals, FDA, Barclays, Thomson Locations: U.S, Bengaluru
0 next >>
Total: 2